Non-Alcoholic Steatohepatitis (NASH) accounts for 6.3% share of global Gastrointestinal clinical trial activity in 2021
Non-Alcoholic Steatohepatitis (NASH) accounted for a 6.3% share of the global clinical trials within the Gastrointestinal therapy area in 2021,…
By